ReviewEye and vision (London, England)2019
Update on pharmacotherapy for ocular surface squamous neoplasia.
Review in Eye and vision (London, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it, 82 citations in OpenAlex.
- Formulation of treatment protocol for ocular surface squamous neoplasia.International ophthalmology · 2026Pooled it
- Safety and efficacy of topical interferon alpha 2B and mitomycin C for localized conjunctival intraepithelial neoplasia: long-term report of their pharmacological safety and efficacy.BMC ophthalmology · 2023Trial
- Review
- New Paradigm in Ocular Surface Squamous Neoplasia-Insights from a Case Report on the Use of Interferon in Treatment.Oncology research · 2026Article
- Case Report: Atypical ocular surface squamous cell carcinoma.Frontiers in medicine · 2026Article
- Presumed reactivation of herpes simplex virus-associated endothelial keratitis after treatment with topical interferon-α 2b for ocular surface squamous neoplasia.BMC ophthalmology · 2025Article
- Update in the Diagnosis and Management of Ocular Surface Squamous Neoplasia (OSSN).Journal of clinical medicine · 2025Review
- Clinical profile and outcomes of ocular surface squamous neoplasia at the Philippine General Hospital: a retrospective study.International journal of ophthalmology · 2025Article
- Topical Chemotherapy for Ocular Surface Squamous Neoplasia: A Review of Adverse Effects and Their Clinical Management.Oncology research · 2025Review
- Topical 5-Fluorouracil 0.5% as primary treatment for Ocular Surface Squamous Neoplasia.European journal of ophthalmology · 2025Article
- Article
- Chronic inflammation as a proposed risk factor for ocular surface squamous neoplasia.The ocular surface · 2024Article
- Case report: Clinical features and management outcomes of isolated corneal intraepithelial neoplasia.Frontiers in ophthalmology · 2024Article
- Update in ocular surface squamous neoplasia.Revista da Associacao Medica Brasileira (1992) · 2024Review
- Asymptomatic chronic red eye: A surgical technique case report.International journal of surgery case reports · 2023Article
- Brachytherapy as a curative option for ocular surface squamous neoplasia.International ophthalmology · 2023Article
- Novel ocular immunotherapy induces tumor regression in an equine model of ocular surface squamous neoplasia.Cancer immunology, immunotherapy : CII · 2023Article
- Mesoporous Silica Nanoparticles Coated with Carboxymethyl Chitosan for 5-Fluorouracil Ocular Delivery: Characterization, In Vitro and In Vivo Studies.Molecules (Basel, Switzerland) · 2023Article
- Epidemiology and survival outcomes of patients with orbital region non-cutaneous squamous cell carcinoma: a population-based analysis.Frontiers in oncology · 2023Article
- The Management of Ocular Surface Squamous Neoplasia (OSSN).International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
The most frequently encountered non-pigmented tumor of the ocular surface is ocular surface squamous neoplasia (OSSN). Over the past two decades, the pharmacological management of OSSN has grown, with topical 5-fluorouracil, mitomycin, and interferon alpha 2b all being successfully used to treat this disease. Other agents, such as anti-vascular endothelial growth factor (VEGF), retinoic acid, cidofovir and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.